Synergistic effects of ICI 182,780 on the cytotoxicity of cisplatin in cervical carcinoma cell lines

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 6, 2004, Pages 533-540

  García López, Patricia ^a   Rodríguez Dorantes, Mauricio ^c   Pérez Cárdenas, Enrique ^a   Cerbón, Marco ^c   Mohar Betancourt, Alejandro ^a,b  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c Universidad Nacional Autonoma de Mexico Facultad de Quimica   (Mexico)

Author keywords

Cancer therapy; Cervical cancer; Cisplatin; Drug synergism; ICI 182,780

Indexed keywords

CISPLATIN; ESTROGEN RECEPTOR; FULVESTRANT; PROGESTERONE RECEPTOR; TETRAZOLIUM;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL DEATH; CONTROLLED STUDY; DATA ANALYSIS; DRUG CYTOTOXICITY; DRUG POTENTIATION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; FLOW CYTOMETRY; FORMAZANS; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; UTERINE CERVICAL NEOPLASMS;

EID: 2542481074     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0760-3     Document Type: Article

References (38)

1. Add S, Yates RA, Laight A (2002) A phase 1 trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestran on the endometrium in healthy postmenopausal volunteers. Br J Cancer 87:1354
2. Benedetti PP, Greggi S, Scambia G (1991) High-dose cisplatin and bleomycin neoadjuvant chemotherapy plus radical surgery in locally advanced cervical carcinoma: a preliminary report. Gynecol Oncol 41:212
3. Branham WS, Fishman R, Streck RD, Medlock KL, De George JJ, Sheehan DM (1996) ICI 182,780 inhibits endogenous estrogen-dependent rat uterine growth and tamoxifen-induced developmental toxicity. Biol Reprod 54:160
4. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of tetrazolium based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936
5. Chan TW, Pollak M, Huynh H (2001) Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780. Clin Cancer Res 7:2545
6. Chou TC (1998) Drug combination: from laboratory to practice. J Lab Clin Med 132:6
7. Chou TC, Motzer RJ, Youzhi Tong, Bosl GJ (1994) Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth a rational approach to clinical protocol design. J Natl Cancer Inst 86:1517
8. Cummings FJ (2002) Evolving uses of hormonal agents for breast cancer therapy. Clin Ther 24:C3
9. DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blamey RW, Bundred NJ, Robertson JF, Saunders C, et al (1994) Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54:408
10. De Vincenzo R, Scambia G, Benedetti PP, Fattorasi A, Bonanno G, Ferlinic C, Isola G, Pernisco S, Mancuso S (1996) Modulatory effects of tamoxifen and ICI 182, 780 on Adriamycin resistance in MCF-7 human breast cancer cells. Int J Cancer 68:340
11. Drucker L, Stackievicz R, Radnay J, Shapira H, Cohen I, Yarkoni S (2003) Tamoxifen enhances apoptotic effect of cisplatin on primary endometrial cell cultures. Anticancer Res 23:1549
12. Fontanelli R, Spatti G, Raspagliesi F, Zunino F (1992) A preoperative single course of high-dose cisplatin and bleomycin with glutathione protection in bulky stage IB carcinoma of the cervix. Ann Oncol 3:117
13. Friedrich M, Mink D, Villena-Heinsen C, Woll-Hermann A, Schmidt W (1998) Tamoxifen and proliferation of vaginal and cervical epithelium in postmenopausal women with breast cancer. Eur J Obstet Gynecol Reprod Biol 80:221
14. Gandara DR, Ferez EA, Wiebe V, De Gregorio MW (1991) Cisplatin chemoprotection and rescue: pharmacological modulation of toxicity. Semin Oncol 18:49
15. Hahnel R, Martin JD, Masters AM, Ratajezak KT, Twaddle E (1979) Estrogen receptors and blood hormone levels in cervical carcinoma and other gynecological tumors. Gynecol Oncol 8:226
16. He Q, Liang CH, Lippard SJ (2000) Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci U S A 97:5768
17. Hirsimak P, Aaltonen A, Mantyla E (2002) Toxicity of antiestrogens. Breast J 8:92
18. Hornback WB, Shen RN, Sutton GP, Shidnia H, Kaiser HE (1994) Synergistic cytotoxic and antitumor effects of irradiation and taxol on human HeLa cervix carcinoma and mouse B16 melanoma cells. In Vivo 8:819
19. Howell A, DeFriend DJ, Robertson JF, Blamey RW, Anderson L, Anderson E, Sutcliffe FA, Walton P (1996) Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182,780 in women with advanced breast cancer. Br J Cancer 74:300
20. Howell A, Osborne CK, Morris C, Wakeling AE (2000) ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer 89:817
21. Huang JC, Zamble DB, Reardon JT, Lippard ST, Sancar A (1994) HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci U S A 91:10394
22. Huynh H, Nickerson T, Pollak M, Yang X (1996) Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182,780. Clin Cancer Res 2:2037
23. Hwang JY, Lin BY, Tang FM, Yu WC (1992) Tamoxifen stimulates human papillomavirus type 16 gene expression and cell proliferation in a cervical cancer cell line. Cancer Res 52:6848
24. Hyder S, Chiappetta C, Murthy L, Stancel G (1997) Selective inhibition of estrogen-regulated gene expression in vivo by the pure antiestrogen ICI 182,780. Cancer Res 57:2547
25. Lackey BR, Gray SL, Henricks DM (2000) Synergistic approach to cancer therapy: exploiting interactions between anti-estrogens, retinoids, monoterpenes and tyrosine kinase inhibitors. Med Hypotheses 54:832
26. Loehrer PJ, Einhorn LH (1984) Cisplatin, diagnosis and treatment. Ann Intern Med 100:704
27. Marino M, Acconcia F, Bresciani F, Weisz A, Trentalance A (2002) Distinct nongenomic signal transduction pathways controlled by 17B-estradiol regulate DNA synthesis and cyclin D1 gene transcription in HepG2 cells. Mol Biol Cell 13:3720
28. Mourits MJ, Hollema H, De Vries EG, Ten-Hoor KA, Willemse PH, VanDer Zee AG (2002) Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium. Hum Pathol 33:341
29. Nooter K, Stoter G (1996) Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract 192:768
30. Ozols RF (1995) Current status of chemotherapy for ovarian cancer. Semin Oncol 22:61
31. Perez EA, Gandara DR, Edelman MJ, O'Donnell R, Lauder IJ, DeGregorio M (2003) Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies. Cancer Invest 21:1
32. Rosenberg Zand RS, Grass L, Magklara A, Jenkins DJ, Diamandis EP (2000) Is ICI 182,780 an antiprogestin in addition to being an antiestrogen?. Breast Cancer Res Treat 60:1
33. Sacks PG, Haris D, Chou TC (1995) Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy. Int J Cancer 61:409
34. Soutter WP, Leake RA (1987) Steroid hormone receptors in gynaecological cancer. In: Bonnard J (ed) Recent advances in obstetrics and gynaecology. Churchill Livingstone, Edinburgh, p 175
35. Tan-Chiu E, Wang J, Costantino JP, Paik S, Butch C, Wickerham DL, Fisher B, Wolmark N (2003) Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J Natl Cancer Inst 95:302
36. Tavassoli M, Soltaninia J, Rudnicka J, Mashanyare D, Johnson N, Gaken J (2002) Tamoxifen inhibits the growth of head and neck cancer cells and sensitizes these cells to cisplatin induced apoptosis: role of TGF-beta1. Carcinogenesis 23:1569
37. Thomas EJ, Walton P, Thomas NM, Dowsett M (1994) The effects of ICI 182,780, a pure anti-estrogen, on the hypothalamic-pituitary-gonadal axis and on endometrial proliferation in pre-menopausal women. Hum Reprod 9:1991
38. Vargas-Roid LM, Lotfi H, Olcese JE, Lo-Castro G, Ciocca DR (1993) Effects of short-term tamoxifen administration in patients with invasive cervical carcinoma. Anticancer Res 13:2457